Document is current
Any future updates will be listed below
-
Authors
Wilson, Jordan C. J. https://orcid.org/0000-0001-7765-8597
Zhu, JiaYi
Vinciauskaite, Vanesa
Lloyd, Eloise G. https://orcid.org/0000-0002-5258-4111
Lam, Simon https://orcid.org/0000-0002-4476-0971
Hart, Alexandra
Goh, Chen Gang
Bou-Dagher, Fadia
Razumkov, Hlib
Kobel, Lena https://orcid.org/0000-0001-7949-141X
Kontarakis, Zacharias https://orcid.org/0000-0001-8825-8513
Fielden, John
Schlapansky, Moritz F.
Loizou, Joanna I. https://orcid.org/0000-0003-1853-0424
Villunger, Andreas https://orcid.org/0000-0001-8259-4153
Corn, Jacob E. https://orcid.org/0000-0002-7798-5309
Biffi, Giulia https://orcid.org/0000-0003-4592-0970
Masson, Glenn R. https://orcid.org/0000-0002-1386-4719
Marciniak, Stefan J. https://orcid.org/0000-0001-8472-7183
Bader, Aldo S.
Jackson, Stephen P. https://orcid.org/0000-0001-9317-7937
- License Information
-
More Information
Article History
Received: 10 March 2025
Accepted: 2 September 2025
First Online: 9 October 2025
Competing interests
: S.P.J. is a founding partner of Ahren Innovation Capital LLP, is co-founder of Mission Therapeutics Ltd., and Chief Research Officer (part-time) of Insmed Innovation UK. J.E.C. is a co-founder and SAB member of Serac Biosciences and an SAB member of Mission Therapeutics, Relation Therapeutics, Hornet Bio, and Kano Therapeutics. The remaining authors declare no competing interests.
